Review
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 21, 2020; 26(23): 3126-3144
Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3126
Table 3 HISORt Criteria for IgG4-related sclerosing cholangitis (Adapted from references[32,44])
Histology (Criterion H)Lymphoplasmacytic infiltrate with > 10 IgG4+ cells per high‐power field within and around bile ducts; obliterative phlebitis; storiform fibrosis
Imaging (Criterion I)Strictures of the biliary tree including intrahepatic ducts, proximal extra-hepatic ducts, intra-pancreatic ducts; fleeting and migrating biliary strictures
Serology (Criterion S)Raised serum IgG4 levels (> 1.35 g/L)
Organ involvement (Criterion O)Extra-biliary manifestations consistent with IgG4-RD, such as: pancreas (focal pancreatic mass/enlargement without pancreatic duct dilatation, multiple pancreatic masses, focal pancreatic duct stricture without upstream dilatation, pancreatic atrophy); retroperitoneal fibrosis; kidney (single or multiple parenchymal low‐attenuation lesions: Round, wedge‐shaped, or diffuse patchy); salivary or lacrimal gland (enlargement)
Response to treatment (Criterion R)Normalisation of liver enzymes and at least partial stricture resolution after steroid treatment